These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 8523579)

  • 1. Single amino acid substitution in constant region 1 or 4 of gp120 causes the phenotype of a human immunodeficiency virus type 1 variant with mutations in hypervariable regions 1 and 2 to revert.
    Wang WK; Essex M; Lee TH
    J Virol; 1996 Jan; 70(1):607-11. PubMed ID: 8523579
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nonrandom distribution of gp120 N-linked glycosylation sites important for infectivity of human immunodeficiency virus type 1.
    Lee WR; Syu WJ; Du B; Matsuda M; Tan S; Wolf A; Essex M; Lee TH
    Proc Natl Acad Sci U S A; 1992 Mar; 89(6):2213-7. PubMed ID: 1549584
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determinants of CD4 independence for a human immunodeficiency virus type 1 variant map outside regions required for coreceptor specificity.
    LaBranche CC; Hoffman TL; Romano J; Haggarty BS; Edwards TG; Matthews TJ; Doms RW; Hoxie JA
    J Virol; 1999 Dec; 73(12):10310-9. PubMed ID: 10559349
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selection for neutralization resistance of the simian/human immunodeficiency virus SHIVSF33A variant in vivo by virtue of sequence changes in the extracellular envelope glycoprotein that modify N-linked glycosylation.
    Cheng-Mayer C; Brown A; Harouse J; Luciw PA; Mayer AJ
    J Virol; 1999 Jul; 73(7):5294-300. PubMed ID: 10364275
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of neutralization epitopes in the V2 region of human immunodeficiency virus type 1 gp120: role of glycosylation in the correct folding of the V1/V2 domain.
    Wu Z; Kayman SC; Honnen W; Revesz K; Chen H; Vijh-Warrier S; Tilley SA; McKeating J; Shotton C; Pinter A
    J Virol; 1995 Apr; 69(4):2271-8. PubMed ID: 7533854
    [TBL] [Abstract][Full Text] [Related]  

  • 6. N-linked glycosylation sites adjacent to and within the V1/V2 and the V3 loops of dualtropic human immunodeficiency virus type 1 isolate DH12 gp120 affect coreceptor usage and cellular tropism.
    Ogert RA; Lee MK; Ross W; Buckler-White A; Martin MA; Cho MW
    J Virol; 2001 Jul; 75(13):5998-6006. PubMed ID: 11390601
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protection of neutralization epitopes in the V3 loop of oligomeric human immunodeficiency virus type 1 glycoprotein 120 by N-linked oligosaccharides in the V1 region.
    Losman B; Bolmstedt A; Schønning K; Björndal A ; Westin C; Fenyö EM; Olofsson S
    AIDS Res Hum Retroviruses; 2001 Jul; 17(11):1067-76. PubMed ID: 11485624
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evidence for a functional interaction between the V1/V2 and C4 domains of human immunodeficiency virus type 1 envelope glycoprotein gp120.
    Freed EO; Martin MA
    J Virol; 1994 Apr; 68(4):2503-12. PubMed ID: 8139032
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Removal of N-linked glycosylation sites in the V1 region of simian immunodeficiency virus gp120 results in redirection of B-cell responses to V3.
    Cole KS; Steckbeck JD; Rowles JL; Desrosiers RC; Montelaro RC
    J Virol; 2004 Feb; 78(3):1525-39. PubMed ID: 14722307
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human immunodeficiency virus type 1 evasion of a neutralizing anti-V3 antibody involves acquisition of a potential glycosylation site in V2.
    Hatada M; Yoshimura K; Harada S; Kawanami Y; Shibata J; Matsushita S
    J Gen Virol; 2010 May; 91(Pt 5):1335-45. PubMed ID: 20032207
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Location-specific, unequal contribution of the N glycans in simian immunodeficiency virus gp120 to viral infectivity and removal of multiple glycans without disturbing infectivity.
    Ohgimoto S; Shioda T; Mori K; Nakayama EE; Hu H; Nagai Y
    J Virol; 1998 Oct; 72(10):8365-70. PubMed ID: 9733886
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resistance of a human serum-selected human immunodeficiency virus type 1 escape mutant to neutralization by CD4 binding site monoclonal antibodies is conferred by a single amino acid change in gp120.
    McKeating JA; Bennett J; Zolla-Pazner S; Schutten M; Ashelford S; Brown AL; Balfe P
    J Virol; 1993 Sep; 67(9):5216-25. PubMed ID: 7688820
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of mutants of human immunodeficiency virus type 1 that have escaped neutralization by a monoclonal antibody to the gp120 V2 loop.
    Yoshiyama H; Mo H; Moore JP; Ho DD
    J Virol; 1994 Feb; 68(2):974-8. PubMed ID: 7507188
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutation of conserved N-glycosylation sites around the CD4-binding site of human immunodeficiency virus type 1 GP120 affects viral infectivity.
    Dirckx L; Lindemann D; Ette R; Manzoni C; Moritz D; Mous J
    Virus Res; 1990 Dec; 18(1):9-20. PubMed ID: 2082620
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship of the human immunodeficiency virus type 1 gp120 third variable loop to a component of the CD4 binding site in the fourth conserved region.
    Wyatt R; Thali M; Tilley S; Pinter A; Posner M; Ho D; Robinson J; Sodroski J
    J Virol; 1992 Dec; 66(12):6997-7004. PubMed ID: 1279195
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Variable-loop-deleted variants of the human immunodeficiency virus type 1 envelope glycoprotein can be stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits.
    Sanders RW; Schiffner L; Master A; Kajumo F; Guo Y; Dragic T; Moore JP; Binley JM
    J Virol; 2000 Jun; 74(11):5091-100. PubMed ID: 10799583
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glycan deletions in the HIV-1 gp120 V1/V2 domain compromise viral infectivity, sensitize the mutant virus strains to carbohydrate-binding agents and represent a specific target for therapeutic intervention.
    Auwerx J; François KO; Covens K; Van Laethem K; Balzarini J
    Virology; 2008 Dec; 382(1):10-9. PubMed ID: 18930512
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Maintenance of syncytium-inducing phenotype of HIV type 1 is associated with positively charged residues in the HIV type 1 gp120 V2 domain without fixed positions, elongation, or relocated N-linked glycosylation sites.
    Cornelissen M; Hogervorst E; Zorgdrager F; Hartman S; Goudsmit J
    AIDS Res Hum Retroviruses; 1995 Oct; 11(10):1169-75. PubMed ID: 8573372
    [TBL] [Abstract][Full Text] [Related]  

  • 19. V2 loop glycosylation of the human immunodeficiency virus type 1 SF162 envelope facilitates interaction of this protein with CD4 and CCR5 receptors and protects the virus from neutralization by anti-V3 loop and anti-CD4 binding site antibodies.
    Ly A; Stamatatos L
    J Virol; 2000 Aug; 74(15):6769-76. PubMed ID: 10888615
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evidence for the cooperation of gp120 amino acids 322 and 448 in SIVmac entry.
    Morrison HG; Kirchhoff F; Desrosiers RC
    Virology; 1993 Jul; 195(1):167-74. PubMed ID: 8317093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.